PACIFIC-R 真实世界中不可切除 III 期 NSCLC 放化疗后度伐利尤单抗治疗的放疗模式与肺炎相关因素
PACIFIC-R 是一项国际观察性研究,纳入 268 例不可切除 III 期 NSCLC 患者,分析放化疗后度伐利尤单抗巩固治疗期间的症状性肺炎(SP)与放疗模式及危险因素。结果显示 19.4% 患者发生 SP,较高的平均肺放疗剂量和既往 COPD 与 SP 风险升高相关。
要点
- 同步放化疗(86.6%)和 IMRT(66.8%)是主要治疗模式。
- 度伐利尤单抗治疗期间 19.4% 患者出现症状性肺炎。
- 较高平均肺剂量和既往 COPD 与 SP 风险升高独立相关。
核心结论
- 在不可切除 III 期 NSCLC 患者中,同步放化疗和 IMRT 是最常见的放疗方式,较高的平均肺放疗剂量和既往 COPD 与度伐利尤单抗巩固治疗期间症状性肺炎风险升高相关。
研究设计与样本
- PACIFIC-R 是一项正在进行的国际观察性研究,基于度伐利尤单抗早期准入计划患者的病历数据,纳入候选 SP 危险因素无缺失数据的患者,共分析 268 例。
主要发现
- 268 例患者中 86.6% 接受同步放化疗、13.4% 接受序贯放化疗,66.8% 接受 IMRT、25.7% 接受三维适形放疗,存在国家间差异。
- 接受 IMRT 的患者年龄更大、非鳞癌组织学更常见且肿瘤更大。
- 多变量 logistic 回归显示,较高的平均肺放疗剂量(对数转换)和既往 COPD 与 SP 风险升高相关,OR(95%CI)分别为 4.73(1.66-15.07)和 2.60(1.21-5.65)。
- 敏感性分析采用 Cox 比例风险模型,对应 HR(95%CI)分别为 3.28(1.54-6.95)和 1.93(1.04-3.56)。
关键数值与推荐
- SP 定义为任何原因的≥2 级肺炎事件或需要皮质类固醇治疗的肺炎。
临床怎么用
- 在不可切除 III 期 NSCLC 患者放化疗后接受度伐利尤单抗巩固治疗时,应关注平均肺放疗剂量和既往 COPD 病史以评估症状性肺炎风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Consolidation durvalumab, standard-of-care treatment for patients with unresectable stage III non-small-cell lung cancer (NSCLC) and no disease progression after chemoradiotherapy, may be associated with pneumonitis. We performed exploratory analyses of radiotherapy patterns and potential risk factors for symptomatic pneumonitis (SP) in PACIFIC-R. MATERIALS AND METHODS: PACIFIC-R is an ongoing, international, observational study based on medical chart data for patients in the durvalumab early access program. Patients with no missing data for candidate SP risk factors were included. SP was defined as a pneumonitis event (any cause) of grade ≥ 2 or requiring corticosteroids. Multivariable logistic regression identified variables associated with SP during durvalumab treatment; sensitivity analyses used a Cox proportional hazards model to account for time to SP. RESULTS: Analyses included 268 patients; most received concurrent (86.6%) versus sequential (13.4%) chemoradiotherapy and intensity-modulated (IMRT; 66.8%) versus three-dimensional conformal (25.7%) radiotherapy, with between-country differences. Patients receiving IMRT were older, more frequently had nonsquamous histology, and had larger tumors. Fifty-two patients (19.4%) had SP during durvalumab treatment. Higher mean lung radiotherapy dose (log transformed) and prior chronic obstructive pulmonary disease (COPD) were associated with higher SP risk, with odds ratios (95% confidence interval [CI]) of 4.73 (1.66-15.07) and 2.60 (1.21-5.65), respectively, and hazard ratios (95% CI) of 3.28 (1.54-6.95) and 1.93 (1.04-3.56), respectively. CONCLUSIONS: Concurrent chemoradiotherapy and IMRT were the most common radiotherapy approaches. Higher mean lung radiotherapy dose and prior COPD were associated with higher SP risk during consolidation durvalumab for unresectable stage III NSCLC.
引用
- Filippi AR, Bar J, Christoph DC, et al. Radiotherapy patterns and factors associated with pneumonitis in PACIFIC-R, a real-world study of patients with unresectable stage III non-small-cell lung cancer treated with durvalumab after chemoradiotherapy. Clin Transl Radiat Oncol. 2026. PMID: 41809542. doi:10.1016/j.ctro.2026.101138
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。